Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -82.08 Million EUR | 8.25% |
| 2022 | -113.44 Million EUR | -84.79% |
| 2021 | -61.39 Million EUR | -11.38% |
| 2020 | -55.12 Million EUR | -6696.55% |
| 2019 | -811 Thousand EUR | -112.95% |
| 2018 | 6.26 Million EUR | 258.35% |
| 2017 | -3.95 Million EUR | 90.71% |
| 2016 | -42.56 Million EUR | -113.54% |
| 2015 | -19.93 Million EUR | 16.3% |
| 2014 | -23.81 Million EUR | -14.2% |
| 2013 | -20.85 Million EUR | -62.52% |
| 2012 | -12.83 Million EUR | -188.32% |
| 2011 | -4.45 Million EUR | 47.12% |
| 2010 | -8.41 Million EUR | -33.71% |
| 2009 | -6.29 Million EUR | -99.59% |
| 2008 | -3.15 Million EUR | 34.09% |
| 2007 | -4.78 Million EUR | -2065.16% |
| 2006 | -221 Thousand EUR | 84.55% |
| 2005 | -1.43 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -24.98 Million EUR | 15.65% |
| 2024 Q1 | -25.54 Million EUR | 13.14% |
| 2023 Q4 | -29.4 Million EUR | -32.38% |
| 2023 Q2 | -18.39 Million EUR | -10.97% |
| 2023 Q3 | -22.21 Million EUR | -20.78% |
| 2023 FY | -104.08 Million EUR | 8.25% |
| 2023 Q1 | -16.57 Million EUR | 70.59% |
| 2022 Q2 | -131.98 Million EUR | -616.47% |
| 2022 Q1 | -18.42 Million EUR | -110.45% |
| 2022 FY | -113.44 Million EUR | -84.79% |
| 2022 Q4 | -56.35 Million EUR | -160.39% |
| 2022 Q3 | 93.31 Million EUR | 170.7% |
| 2021 Q1 | -31.13 Million EUR | -1085.31% |
| 2021 Q2 | -55.03 Million EUR | -76.74% |
| 2021 FY | -61.39 Million EUR | -11.38% |
| 2021 Q4 | 176.21 Million EUR | 216.37% |
| 2021 Q3 | -151.43 Million EUR | -175.16% |
| 2020 Q2 | -22.01 Million EUR | -25118.18% |
| 2020 Q4 | -2.62 Million EUR | 91.41% |
| 2020 FY | -55.12 Million EUR | -6696.55% |
| 2020 Q1 | 88 Thousand EUR | -96.39% |
| 2020 Q3 | -30.56 Million EUR | -38.83% |
| 2019 Q2 | -7.95 Million EUR | -228.14% |
| 2019 Q4 | 2.43 Million EUR | 262.29% |
| 2019 FY | -811 Thousand EUR | -112.95% |
| 2019 Q1 | 6.2 Million EUR | 16.11% |
| 2019 Q3 | -1.5 Million EUR | 81.12% |
| 2018 Q1 | 3.2 Million EUR | 177.23% |
| 2018 FY | 6.26 Million EUR | 258.35% |
| 2018 Q4 | 5.34 Million EUR | 494.03% |
| 2018 Q3 | -1.35 Million EUR | -46.12% |
| 2018 Q2 | -928 Thousand EUR | -128.98% |
| 2017 FY | -3.95 Million EUR | 90.71% |
| 2017 Q4 | -4.14 Million EUR | -155.3% |
| 2017 Q2 | 1.34 Million EUR | 181.72% |
| 2017 Q3 | -1.62 Million EUR | -221.1% |
| 2017 Q1 | 476 Thousand EUR | 113.64% |
| 2016 Q1 | -2.72 Million EUR | -3.62% |
| 2016 FY | -42.56 Million EUR | -113.54% |
| 2016 Q4 | -3.49 Million EUR | 13.22% |
| 2016 Q3 | -4.02 Million EUR | 87.56% |
| 2016 Q2 | -32.33 Million EUR | -1088.31% |
| 2015 Q2 | -8.69 Million EUR | -45.81% |
| 2015 Q1 | -5.96 Million EUR | 39.48% |
| 2015 FY | -19.93 Million EUR | 16.3% |
| 2015 Q4 | -2.62 Million EUR | 1.06% |
| 2015 Q3 | -2.65 Million EUR | 69.47% |
| 2014 Q4 | -9.85 Million EUR | -228.7% |
| 2014 Q3 | -2.99 Million EUR | 33.71% |
| 2014 Q1 | -6.44 Million EUR | -82.28% |
| 2014 FY | -23.81 Million EUR | -14.2% |
| 2014 Q2 | -4.52 Million EUR | 29.9% |
| 2013 Q2 | -5.02 Million EUR | -107.18% |
| 2013 Q3 | -9.6 Million EUR | -91.3% |
| 2013 Q1 | -2.42 Million EUR | 32.2% |
| 2013 FY | -20.85 Million EUR | -62.52% |
| 2013 Q4 | -3.53 Million EUR | 63.17% |
| 2012 Q4 | -3.57 Million EUR | -48.28% |
| 2012 Q3 | -2.41 Million EUR | 0.0% |
| 2012 FY | -12.83 Million EUR | -188.32% |
| 2011 FY | -4.45 Million EUR | 47.12% |
| 2010 FY | -8.41 Million EUR | -33.71% |
| 2009 FY | -6.29 Million EUR | -99.59% |
| 2008 FY | -3.15 Million EUR | 34.09% |
| 2007 FY | -4.78 Million EUR | -2065.16% |
| 2006 FY | -221 Thousand EUR | 84.55% |
| 2005 FY | -1.43 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -14.35% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 1770.196% |
| SQZ Biotechnologies Company | -75.82 Million USD | -8.258% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -359.948% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 200.287% |
| Mesoblast Limited | -84.14 Million USD | 2.448% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -5244.035% |
| Genus plc | 6.4 Million USD | 1382.609% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 942.57% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -8713.481% |
| Marizyme, Inc. | -34.08 Million USD | -140.82% |
| ContraFect Corporation | -56.88 Million USD | -44.293% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -883.078% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -1702.238% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -5755.03% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -2779.733% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -2884.071% |
| MultiCell Technologies, Inc. | -722.81 USD | -11356549.742% |
| Accustem Sciences Inc. | -3.74 Million USD | -2091.079% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -39.154% |
| EV Biologics, Inc. | -483.06 Thousand USD | -16893.057% |
| Q BioMed Inc. | -3.44 Million USD | -2282.361% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 2418.842% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -20971.181% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -3024.122% |
| Biomind Labs Inc. | -1 Million USD | -8030.622% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -1582.268% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -1134.76% |
| Skye Bioscience, Inc. | -13.67 Million USD | -500.411% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -4032.286% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -273961.832% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -1527.263% |
| IMV Inc. | -38.67 Million USD | -112.267% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -417.255% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -4147.468% |
| GB Sciences, Inc. | -1.42 Million USD | -5678.703% |
| Alpha Cognition Inc. | -9.7 Million USD | -745.769% |
| HST Global, Inc. | -140.9 Thousand USD | -58156.155% |
| CSL Limited | 3.7 Billion USD | 102.217% |
| Halberd Corporation | -75.05 Thousand USD | -109276.416% |
| Enzolytics Inc. | -2.14 Million USD | -3720.132% |
| Resverlogix Corp. | -12.74 Million USD | -543.87% |
| Affymax, Inc. | -15.04 Million USD | -445.574% |
| SYBLEU INC | -149.18 Thousand USD | -54925.473% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -2490.906% |
| argenx SE | -425.04 Million USD | 80.688% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -47.883% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -7762.739% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -5097.502% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -2310.793% |
| AVAX Technologies, Inc. | 6.69 Million USD | 1326.482% |
| Zenith Capital Corp. | -8.94 Million USD | -817.891% |
| Genscript Biotech Corporation | -415.79 Million USD | 80.258% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -471095.683% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -3243.234% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -47761.478% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -49.324% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -2729.367% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -8241.725% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -4302.935% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -6435.589% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -3994.611% |
| BioStem Technologies, Inc. | -7.77 Million USD | -955.243% |
| ONE Bio Corp. | 13.68 Million USD | 699.983% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -45130.735% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -6046.854% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -7197.232% |
| Agentix Corp. | -1.37 Million USD | -5884.082% |
| LadRx Corporation | -3.82 Million USD | -2046.837% |
| Cell Source, Inc. | -4.32 Million USD | -1797.813% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -19657.196% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -11849.487% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -11849.487% |
| NovAccess Global Inc. | -2.46 Million USD | -3227.725% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -2711.734% |
| Itoco Inc. | -919.14 Thousand USD | -8830.848% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -1836.739% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -7235.746% |
| Kadimastem Ltd | -3.04 Million USD | -2600.008% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -31263.716% |
| CytoDyn Inc. | -18.05 Million USD | -354.574% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -326030.314% |
| Mobile Lads Corp. | -554.55 Thousand USD | -14702.452% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -37199.049% |
| Qrons Inc. | -643.67 Thousand USD | -12652.825% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -14435.799% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -3581.231% |
| Rebus Holdings, Inc. | -664 Thousand USD | -12262.5% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -4419.413% |
| International Stem Cell Corporation | -663 Thousand USD | -12281.146% |
| Bioxytran, Inc. | -3.82 Million USD | -2048.792% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -155840.35% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -403474.238% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -126.347% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -4973.362% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -11055.626% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -2538.605% |
| Neutra Corp. | -229.48 Thousand USD | -35669.938% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -368.026% |
| PureTech Health plc | -146.19 Million USD | 43.853% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -281.958% |
| IXICO plc | -1.43 Million USD | -5612.387% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -764.893% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 32.608% |
| CSL Limited | 3.81 Billion USD | 102.153% |
| Cellectis S.A. | -108.85 Million USD | 24.592% |